The Challenge
Marta wanted to join a KRAS G12D trial but was considering a nuclear medicine study that she thought might apply. Confusion over trial eligibility and outdated biomarker reports left her uncertain about next steps.
Our Impact
Cancer Commons clarified that the nuclear medicine study was unlikely to benefit her, explained the basics of first-in-human safety trials, and refocused attention on KRAS-targeted trials aligned with her tumor profile. We recommended a liquid biopsy to capture up-to-date genetic data, curated a table of relevant trials, and advised a second opinion at a top cancer center in the region.
The Outcome
Marta avoided spending time and energy on an irrelevant study, gained a clear roadmap of actionable KRAS-focused trials, and took immediate steps by arranging a liquid biopsy and planning for an expert second opinion.
